IN2015DN03326A - - Google Patents
Info
- Publication number
- IN2015DN03326A IN2015DN03326A IN3326DEN2015A IN2015DN03326A IN 2015DN03326 A IN2015DN03326 A IN 2015DN03326A IN 3326DEN2015 A IN3326DEN2015 A IN 3326DEN2015A IN 2015DN03326 A IN2015DN03326 A IN 2015DN03326A
- Authority
- IN
- India
- Prior art keywords
- mva
- antigen
- recombinant
- immunizations
- viruses
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010046865 Vaccinia virus infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 208000007089 vaccinia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719429P | 2012-10-28 | 2012-10-28 | |
| PCT/EP2013/003239 WO2014063832A1 (en) | 2012-10-28 | 2013-10-28 | Pr13.5 promoter for robust t-cell and antibody responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03326A true IN2015DN03326A (https=) | 2015-10-09 |
Family
ID=49513897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3326DEN2015 IN2015DN03326A (https=) | 2012-10-28 | 2013-10-28 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9828414B2 (https=) |
| EP (2) | EP2912183B1 (https=) |
| JP (2) | JP6505016B2 (https=) |
| KR (2) | KR102135818B1 (https=) |
| CN (1) | CN104755622B (https=) |
| AU (1) | AU2013337018B2 (https=) |
| BR (1) | BR112015009320A2 (https=) |
| CA (1) | CA2887623C (https=) |
| CY (1) | CY1123181T1 (https=) |
| DK (1) | DK2912183T3 (https=) |
| EA (2) | EA201990114A1 (https=) |
| ES (1) | ES2800623T3 (https=) |
| HK (1) | HK1212383A1 (https=) |
| HU (1) | HUE049706T2 (https=) |
| IL (1) | IL238130B (https=) |
| IN (1) | IN2015DN03326A (https=) |
| LT (1) | LT2912183T (https=) |
| MX (2) | MX380483B (https=) |
| MY (2) | MY194609A (https=) |
| NZ (1) | NZ706637A (https=) |
| PT (1) | PT2912183T (https=) |
| SG (2) | SG10201704657WA (https=) |
| SI (1) | SI2912183T1 (https=) |
| UA (1) | UA118340C2 (https=) |
| WO (1) | WO2014063832A1 (https=) |
| ZA (1) | ZA201502892B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9828414B2 (en) * | 2012-10-28 | 2017-11-28 | Bavarian Nordic A/S | Pr13.5 promoter for robust T-cell and antibody responses |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| US10881725B2 (en) | 2016-01-29 | 2021-01-05 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| CA3036799C (en) | 2016-09-28 | 2025-05-13 | Bavarian Nordic A/S | COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
| CN110958887B (zh) | 2017-06-15 | 2023-10-31 | 扬森疫苗与预防公司 | 编码hiv抗原的痘病毒载体及其使用方法 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| KR102754876B1 (ko) | 2017-08-24 | 2025-01-13 | 버베리안 노딕 에이/에스 | 재조합 mva 및 항체의 정맥내 투여에 의한 암 치료를 위한 병용 요법 |
| CN111741766A (zh) | 2017-12-19 | 2020-10-02 | 杨森科学爱尔兰无限公司 | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 |
| GB201807932D0 (en) | 2018-05-16 | 2018-06-27 | Redchenko Irina | Compositions and methods for inducing an immune response |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CN110904127B (zh) | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| CN114867491B (zh) | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| CA3181431A1 (en) | 2020-06-10 | 2021-12-16 | Jurgen Hausmann | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| IL311078A (en) | 2021-09-03 | 2024-04-01 | Bavarian Nordic As | Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) |
| US20250049903A1 (en) | 2021-12-23 | 2025-02-13 | Bavarian Nordic A/S | Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| JP2025525380A (ja) | 2022-06-29 | 2025-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換え改変ｓａＲＮＡ（ＶＲＰ）及びワクシニアウイルスアンカラ（ＭＶＡ）プライム－ブーストレジメン |
| CA3261778A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | CHIMERIC POXVIRUSES |
| EP4648781A1 (en) | 2023-01-12 | 2025-11-19 | Bavarian Nordic A/S | Recombinant modified sarna (vrp) for cancer vaccine |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2025238218A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding antigen-displaying protein nanoparticles |
| WO2025238219A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles |
| WO2025238220A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles |
| WO2025238221A1 (en) | 2024-05-17 | 2025-11-20 | Bavarian Nordic A/S | Viral vectors encoding multi-antigen-displaying protein nanoparticles |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| ES2424847T3 (es) | 2004-06-25 | 2013-10-09 | Merial Ltd. | Genes del virus de la fiebre aftosa que expresan avipox recombinantes |
| JP2008301792A (ja) | 2007-06-11 | 2008-12-18 | National Univ Corp Shizuoka Univ | 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法 |
| JP2012509678A (ja) | 2008-11-27 | 2012-04-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組換えウイルス発現のためのプロモーター |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US9828414B2 (en) * | 2012-10-28 | 2017-11-28 | Bavarian Nordic A/S | Pr13.5 promoter for robust T-cell and antibody responses |
-
2013
- 2013-10-28 US US14/437,939 patent/US9828414B2/en active Active
- 2013-10-28 IN IN3326DEN2015 patent/IN2015DN03326A/en unknown
- 2013-10-28 MX MX2015005264A patent/MX380483B/es unknown
- 2013-10-28 CA CA2887623A patent/CA2887623C/en active Active
- 2013-10-28 KR KR1020157009206A patent/KR102135818B1/ko active Active
- 2013-10-28 PT PT137838520T patent/PT2912183T/pt unknown
- 2013-10-28 HU HUE13783852A patent/HUE049706T2/hu unknown
- 2013-10-28 MY MYPI2018001787A patent/MY194609A/en unknown
- 2013-10-28 HK HK16100267.8A patent/HK1212383A1/xx unknown
- 2013-10-28 EA EA201990114A patent/EA201990114A1/ru unknown
- 2013-10-28 NZ NZ706637A patent/NZ706637A/en unknown
- 2013-10-28 SG SG10201704657WA patent/SG10201704657WA/en unknown
- 2013-10-28 AU AU2013337018A patent/AU2013337018B2/en active Active
- 2013-10-28 MY MYPI2015701223A patent/MY171687A/en unknown
- 2013-10-28 EA EA201590831A patent/EA032498B1/ru not_active IP Right Cessation
- 2013-10-28 WO PCT/EP2013/003239 patent/WO2014063832A1/en not_active Ceased
- 2013-10-28 LT LTEP13783852.0T patent/LT2912183T/lt unknown
- 2013-10-28 KR KR1020207020263A patent/KR20200087880A/ko not_active Ceased
- 2013-10-28 DK DK13783852.0T patent/DK2912183T3/da active
- 2013-10-28 ES ES13783852T patent/ES2800623T3/es active Active
- 2013-10-28 SG SG11201503200PA patent/SG11201503200PA/en unknown
- 2013-10-28 CN CN201380054013.0A patent/CN104755622B/zh active Active
- 2013-10-28 EP EP13783852.0A patent/EP2912183B1/en active Active
- 2013-10-28 JP JP2015538330A patent/JP6505016B2/ja active Active
- 2013-10-28 BR BR112015009320A patent/BR112015009320A2/pt not_active Application Discontinuation
- 2013-10-28 UA UAA201505223A patent/UA118340C2/uk unknown
- 2013-10-28 SI SI201331731T patent/SI2912183T1/sl unknown
- 2013-10-28 EP EP20172647.8A patent/EP3778904A1/en active Pending
-
2015
- 2015-04-02 IL IL238130A patent/IL238130B/en active IP Right Grant
- 2015-04-24 MX MX2021001638A patent/MX2021001638A/es unknown
- 2015-04-28 ZA ZA2015/02892A patent/ZA201502892B/en unknown
-
2017
- 2017-11-22 US US15/821,035 patent/US11028130B2/en active Active
-
2019
- 2019-03-22 JP JP2019054129A patent/JP6818797B2/ja active Active
-
2020
- 2020-07-08 CY CY20201100630T patent/CY1123181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03326A (https=) | ||
| NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| JP2015533841A5 (https=) | ||
| MX349096B (es) | Anticuerpos anti-pd-l1 y sus usos. | |
| PE20142406A1 (es) | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna | |
| NZ708144A (en) | Recombinant adenoviruses and use thereof | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| AR093394A1 (es) | Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos | |
| MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| EA201590304A1 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса | |
| MX2014015977A (es) | Vacuna de adn para usarse en pacientes con cancer pancreatico. | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| MX360415B (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
| WO2012106231A3 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses | |
| AU2013358947A8 (en) | WT1 vaccine | |
| PH12013500204A1 (en) | Polypeptides for treating and/or limiting influenza infection | |
| EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| BR112015025697A2 (pt) | cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante | |
| WO2013138259A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| WO2014015287A3 (en) | Influenza vaccine consisting of a mva which expresses influenza antigens fused to vaccinia secretory signal sequences | |
| MX374919B (es) | ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae. | |
| NZ618125A (en) | Genetic vaccines against hendra virus and nipah virus |